Table II.
The five long non-coding RNAs significantly associated with prognosis of lung adenocarcinoma patients in the training cohort.
| Gene name | Ensemble ID | Chromosomal position | Hazard ratioa | Coefficienta | P-valuea |
|---|---|---|---|---|---|
| OGFRP1 | ENSG00000182057.4 | chr22: 42,269,753-42,275,196 | 1.52 (1.18–1.97) | 0.419 | 0.001 |
| ITGB1-DT | ENSG00000229656 | chr10: 32,958,845-33,082,102 | 1.12 (1.01–1.23) | 0.109 | 0.023 |
| LMO7DN | ENSG00000178734 | chr13: 75,871,038-75,883,811 | 0.83 (0.72–0.96) | −0.186 | 0.014 |
| NPSR1-AS1 | ENSG00000197085.7 | chr7: 34,346,512-34,871,582 | 1.17 (1.04–1.31) | 0.155 | 0.008 |
| PRKG1-AS1 | ENSG00000236671 | chr10: 52,230,742-52,314,507 | 1.16 (1.13–1.31) | 0.151 | 0.015 |
a
Derived from the multivariate Cox regression analysis of 264 lung adenocarcinoma patients in the training cohort. OGFRP1, opioid growth factor receptor pseudogene 1; ITGB1-DT, integrin subunit beta 1 divergent transcript; LMO7DN, LIM domain 7 downstream neighbor; NPSR1-AS1, neuropeptide S receptor 1-antisense RNA 1; PRKG1-AS1, protein kinase cyclic GMP-dependent 1-antisense RNA 1; chr, chromatin.